Role of ProstaScint® for brachytherapy in localized prostate adenocarcinoma

Rodney J. Ellis, Edward Kim, Ryan Foor

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

ProstaScint® (CYT-356 or capromab pendetide, Cytogen) is an 111in-labeled monoclonal mouse antibody specific for prostate-specific membrane antigen, a prostate transmembrane glycoprotein that is upregulated in prostate adenocarcinoma. ProstaScint scans are US Food and Drug Administration approved for pretreatment evaluation of metastatic disease in high-risk patients. They are also approved for post-prostatectomy assessment of recurrent disease in patients with a rising prostate-specific antigen level. This review explores the literature on ProstaScint and its use in guiding the treatment of prostate cancer. A novel technique for identifying areas of cancer within the prostate using ProstaScint images fused with pelvic computed tomography scans is also described. The identification of areas of high antibody signal provides targets for radiotherapeutic dose escalation, with the overall goals of improving treatment outcome while preserving adjacent tissue structures and decreasing treatment morbidity.

Original languageEnglish (US)
Pages (from-to)435-441
Number of pages7
JournalExpert Review of Molecular Diagnostics
Volume4
Issue number4
DOIs
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Brachytherapy
Prostate
Adenocarcinoma
Prostatic Neoplasms
United States Food and Drug Administration
Prostate-Specific Antigen
Prostatectomy
Capromab Pendetide
Glycoproteins
Monoclonal Antibodies
Tomography
Morbidity
Antibodies
Therapeutics

Keywords

  • Brachytherapy
  • ProstaScint®
  • Prostate
  • Radioimmunoguided

ASJC Scopus subject areas

  • Genetics

Cite this

Role of ProstaScint® for brachytherapy in localized prostate adenocarcinoma. / Ellis, Rodney J.; Kim, Edward; Foor, Ryan.

In: Expert Review of Molecular Diagnostics, Vol. 4, No. 4, 07.2004, p. 435-441.

Research output: Contribution to journalArticle

@article{c4055008919e4496bd8013447f022e96,
title = "Role of ProstaScint{\circledR} for brachytherapy in localized prostate adenocarcinoma",
abstract = "ProstaScint{\circledR} (CYT-356 or capromab pendetide, Cytogen) is an 111in-labeled monoclonal mouse antibody specific for prostate-specific membrane antigen, a prostate transmembrane glycoprotein that is upregulated in prostate adenocarcinoma. ProstaScint scans are US Food and Drug Administration approved for pretreatment evaluation of metastatic disease in high-risk patients. They are also approved for post-prostatectomy assessment of recurrent disease in patients with a rising prostate-specific antigen level. This review explores the literature on ProstaScint and its use in guiding the treatment of prostate cancer. A novel technique for identifying areas of cancer within the prostate using ProstaScint images fused with pelvic computed tomography scans is also described. The identification of areas of high antibody signal provides targets for radiotherapeutic dose escalation, with the overall goals of improving treatment outcome while preserving adjacent tissue structures and decreasing treatment morbidity.",
keywords = "Brachytherapy, ProstaScint{\circledR}, Prostate, Radioimmunoguided",
author = "Ellis, {Rodney J.} and Edward Kim and Ryan Foor",
year = "2004",
month = "7",
doi = "10.1586/14737159.4.4.435",
language = "English (US)",
volume = "4",
pages = "435--441",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Role of ProstaScint® for brachytherapy in localized prostate adenocarcinoma

AU - Ellis, Rodney J.

AU - Kim, Edward

AU - Foor, Ryan

PY - 2004/7

Y1 - 2004/7

N2 - ProstaScint® (CYT-356 or capromab pendetide, Cytogen) is an 111in-labeled monoclonal mouse antibody specific for prostate-specific membrane antigen, a prostate transmembrane glycoprotein that is upregulated in prostate adenocarcinoma. ProstaScint scans are US Food and Drug Administration approved for pretreatment evaluation of metastatic disease in high-risk patients. They are also approved for post-prostatectomy assessment of recurrent disease in patients with a rising prostate-specific antigen level. This review explores the literature on ProstaScint and its use in guiding the treatment of prostate cancer. A novel technique for identifying areas of cancer within the prostate using ProstaScint images fused with pelvic computed tomography scans is also described. The identification of areas of high antibody signal provides targets for radiotherapeutic dose escalation, with the overall goals of improving treatment outcome while preserving adjacent tissue structures and decreasing treatment morbidity.

AB - ProstaScint® (CYT-356 or capromab pendetide, Cytogen) is an 111in-labeled monoclonal mouse antibody specific for prostate-specific membrane antigen, a prostate transmembrane glycoprotein that is upregulated in prostate adenocarcinoma. ProstaScint scans are US Food and Drug Administration approved for pretreatment evaluation of metastatic disease in high-risk patients. They are also approved for post-prostatectomy assessment of recurrent disease in patients with a rising prostate-specific antigen level. This review explores the literature on ProstaScint and its use in guiding the treatment of prostate cancer. A novel technique for identifying areas of cancer within the prostate using ProstaScint images fused with pelvic computed tomography scans is also described. The identification of areas of high antibody signal provides targets for radiotherapeutic dose escalation, with the overall goals of improving treatment outcome while preserving adjacent tissue structures and decreasing treatment morbidity.

KW - Brachytherapy

KW - ProstaScint®

KW - Prostate

KW - Radioimmunoguided

UR - http://www.scopus.com/inward/record.url?scp=3142717474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142717474&partnerID=8YFLogxK

U2 - 10.1586/14737159.4.4.435

DO - 10.1586/14737159.4.4.435

M3 - Article

VL - 4

SP - 435

EP - 441

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 4

ER -